Jason Compton
Optometrist · New York, NYNPI 1205037363
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $112,617 of the $181,459 with a category attached, or 62.1%. Alcon accounts for 93.3% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $117,875, more than ten times the $450 reported in 2019. Among optometrist clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 309 payments — averaging $587.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$169K
- Coopervision Inc.$7K
- Johnson & Johnson Vision Care, Inc.$3K
- Bausch & Lomb Americas Inc.$1K
- Tarsus Pharmaceuticals, Inc.$421
- Topcon Healthcare, Inc.$395
- plus $700 from 11 others
Across 6 payments — averaging $2519.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$15K
What the payments were for
- Consulting fees$112,61762%
- Speaking & faculty fees$35,25019%
- Travel & lodging$23,30913%
- Food & beverage$10,2826%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 227 | $169,265 |
| Coopervision Inc. | 24 | $6,613 |
| Johnson & Johnson Vision Care, Inc. | 9 | $2,661 |
| Bausch & Lomb Americas Inc. | 17 | $1,404 |
| Tarsus Pharmaceuticals, Inc. | 11 | $421 |
| Topcon Healthcare, Inc. | 3 | $395 |
| AbbVie(2 entities) | 6 | $210 |
| Sun Pharmaceutical Industries Inc. | 1 | $125 |
| Dompe US, Inc. | 1 | $124 |
| Carl Zeiss Meditec, Inc. | 2 | $67 |
| Glaukos Corporation | 1 | $46 |
| Sunovion Pharmaceuticals Inc. | 2 | $28 |
| Harrow Eye, LLC | 1 | $27 |
| Sight Sciences, Inc. | 1 | $22 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $18 |
| Amgen | 1 | $17 |
| Visioneering Technologies, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TOTAL30$98,898
- Precision7$98,789
- DAILIES TOTAL1$89,610
- Precision 1$84,331
- Precision 7$19,347
- MiSight Contact Lens$2,500
- Acuvue$2,305
- Onefit Contact Lens$2,000
- MIEBO$991
- XIIDRA$866
- AIR OPTIX$420
- DAILIES TOTAL1 Multifocal$350
- VYZULTA$145
- CEQUA$125
- Oxervate$124
- LOTEMAX SM$103
How this compares
$181,459 in reported general payments places this provider in the 95th percentile of 2,743 optometrist providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 122 | $100,208 |
| MieboPerfluorohexyloctane/Pf | 107 | $77,241 |
| XiidraLifitegrast | 32 | $37,112 |
| LumiganBimatoprost | 126 | $35,286 |
| CombiganBrimonidine Tartrate/Timolol | 62 | $13,770 |
| Brimonidine Tartrate | 99 | $3,266 |
| Timolol Maleate | 58 | $2,557 |
| Latanoprost | 382 | $1,944 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 17 | $1,483 |
| Azelastine Hcl | 156 | $979 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 66 | $750 |
| Travoprost | 13 | $588 |
| Dorzolamide Hcl | 35 | $421 |
| Prednisolone Acetate | 16 | $387 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 30 | $264 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $210 | $149,264310 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $1,404 | $114,353139 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,743 optometrist providers in New York.
Other optometrist in New York
- Susan ResnickNew York$463K
- Denise WhittamNew York$343K
- Jennifer TsaiNew York$275K
- Sophia VisanjiNew York$233K
- Richard MadonnaNew York$75K
- George ZikosNew York$72K
- Craig TischNew York$59K
- Arthur JungNew York$50K
- Milly MuiNew York$46K
- Arkady SelenowNew York$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.